{
    "clinical_study": {
        "@rank": "43377", 
        "arm_group": [
            {
                "arm_group_label": "concurrent chemoradiotherapy plus DC-CIK immunotherapy", 
                "arm_group_type": "Experimental", 
                "description": "patients will receive concurrent chemoradiotherapy plur DC-CIK immunotherapy"
            }, 
            {
                "arm_group_label": "Concurrent chemoradiation only", 
                "arm_group_type": "Active Comparator", 
                "description": "patients will receive concurrent chemoradiotherapy only"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to show if the adoptive cellular therapy with autologous\n      dendritic cells and cytokine-induced killer cells (CIK) combined with concurrent\n      chemoradiation could improve the quality of life of the patients with locally advanced\n      esophageal cancer, compared with concurrent chemoradiation only."
        }, 
        "brief_title": "Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Esophageal Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Esophageal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  cytologically or histologically confirmed locally advanced esophageal carcinoma\n\n          -  Age: > 18\n\n          -  Karnofsky performance status \u2265 70\n\n          -  At least one measurable tumor lesions according to the RECIST criteria.\n\n          -  Normal functions of heart, lung, liver, kidney and bone marrow\n\n          -  Blood exams qualified for chemotherapy, which included hemoglobulin \u22659 g/dl,\n             neutrophil \u22651.5\u00d7109/L and platelet (PLT) \u2265100\u00d7109/L, creatinine \u22641.5 UNL\n\n          -  Informed consent signed\n\n        Exclusion Criteria:\n\n          -  Patients with metastatic disease in the central nervous system (CNS).\n\n          -  Patients who are pregnant or nursing.\n\n          -  Patients with poor bone marrow, liver and kidney functions, which would make\n             chemotherapy intolerable\n\n          -  Patients with contraindication for irradiation: complete obstruction of esophagus,\n             deep esophageal ulcer, fistula to mediastinum, or haematemesis\n\n          -  coexisted morbidities that investigators believed not suitable for chemoradiation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01691625", 
            "org_study_id": "JR-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "concurrent chemoradiotherapy plus DC-CIK immunotherapy", 
                "description": "Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.\nChemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.\nDC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period.", 
                "intervention_name": "concurrent chemoradiotherapy plus DC-CIK immunotherapy", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Concurrent chemoradiation only", 
                "description": "Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.\nChemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.", 
                "intervention_name": "Concurrent chemoradiation only", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Locally advanced esophageal carcinoma", 
            "DC-CIK", 
            "Immunotherapy"
        ], 
        "lastchanged_date": "July 22, 2013", 
        "location": {
            "contact": {
                "email": "renjun9688@yahoo.com", 
                "last_name": "Jun Ren, MD, PhD", 
                "phone": "86-10-63926317"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100038"
                }, 
                "name": "Capital Medical University Cancer Center"
            }, 
            "investigator": {
                "last_name": "Jun Ren, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "description": "Cytokine secretion and T cell populations are assessed.", 
            "measure": "Immunological assessment", 
            "safety_issue": "No", 
            "time_frame": "baseline, months 1, 3, 6 and 12"
        }, 
        "overall_contact": {
            "email": "renjun9688@yahoo.com", 
            "last_name": "Jun Ren, MD, PhD", 
            "phone": "86-10-63926317"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China:State Food and Drug Administraion"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the quality of life", 
            "safety_issue": "No", 
            "time_frame": "initial assessment, months 1, 3, 6 and 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01691625"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Capital Medical University", 
            "investigator_full_name": "Jun Ren MD, PhD", 
            "investigator_title": "Director,Capital Medical University (CMU)Cancer Center,", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "progression-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "source": "Capital Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Capital Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}